Introduction
Thyrotropin -releasing hormone (TRH) is a hypophysiotrophic hormone known to evoke the release of thyroid stimulating hormone.
TRH is widely distributed in extrahypothalamic regions of the brain (Jackson and Reichlin, 1974; Morley, 1979) , and has been shown to exert a number of neuropharmacological actions (Yarbrouh, 1979) . Administration of TRH causes a variety of central effects (Morley, 1979) , including increased motor activity (Havlicek et al. 1976 ), shortened pentobarbitalor ethanol-induced sleeping time (Breese et al. 1974 ) and blockade of the depressant action of a -methyl -p -tyrosine (Kulig, 1975 
Results
The administration of 20 mg/kg, i. p., of DN -1417 markedly increased spontaneous motor activity, as described by Miyamoto et al. (1981) . This effect lasted for at least 2 hours after the injection and occurred with each injection throughout the 7-day treatment period (Fig. 2) . The TH activity, 2 hours after the last of the 7 daily injections of DN -1417 (20 mg/kg), is summarized in Table 1 . A signif icant decrease in TH activity was found in the polar (-49 %), medial (-37%) and lateral (-28%) fields of the prefrontal cortex, mesocortical dopamine terminals which originate in the A10 dopamine cell group.
In the mesolimbic dopamine termini regions of the A10 dopamine cell group, the activity was significantly decreased in the olfactory tuberculum (-28 % ) but unchanged in the nucleus accumbens. There was a significant increase of the activity (49%) in the ventral tegmental area. A marked increase in TH activity (49%) was observed in the locus coeruleus which contains A6 noradrenaline cell bodies; however in the terminal region, the nucleus paraventricularis, the enzyme activity was decreased (-35 %). In the tuberoinfundibular dopamine system, the TH activity in the arcuate nucleus (A12 dopamine cell group) was increased (35 %); however the activity in the median emi - and substantia nigra pars compacta (A9 dopamine cell group).
Discussion
The present study indicates that chronic DN-1417 treatment increased the TH activity in A6 noradrenergic cell bodies and did not changed or decreased the TH activity in the terminals, when the activity was assayed at optimal pH and in the presence of saturated cofactor. The increased activity in A6 noradrenergic cell bodies may be due to an increase in TH concentration.
Thus, Zigmond et al. (1974; 1979) have shown that the TH activity in the locus coeruleus is increased after administration of reserpine or after exposure to cold stress. This increase in the activity results from an increase in the number of TH molecules (Refs et al. 1974) . Furthermore, Black (1975) has demonstrated that the TH activity is increased in the cerebral cortical and cerebellar axon terminals, as well as the locus coeruleus, after reserpine; but the enzyme activity peaked at 3 days in the locus coeruleus, 6 days in the cerebellum, and 11 days in the frontal cortex. The failure to detect the increased activity in the terminal regions, prefrontal cortices and paraventricular nucleus, suggests that the TH molecules induced by DN -1417 in A6 noradrenergic cell bodies do not reach the terminal regions by the 7th day after initiating the treatment.
On the other hand, biochemical studies suggest that TRH enhances noradrenaline turnover in the brain. For example, Reigle et al. (1974) reported that the 3H-normetanephrine level was elevated following intracisternal administration of 3H -noradrenaline in rats pretreated chronically with TRH. Keller et al. (1974) ob-served high levels of 4 -hydroxy -3 -methoxyphenyl glycol, a metabolite of noradrenaline, in rat brains after acute administration of TRH. Moreover, chronic TRH treatment has been shown to induce a dosedependent increase of TH activity in rat brain stem without changing the noradrenaline levels (Agarwal, 1977) . Chronic administration of DN -1417 may also induce an increase in noradrenaline release which could be followed by TH induction in the locus coeruleus.
The TH activity measured at optimal pH and in the presence of saturated pterin cofactor is known to be relatively insensitive to short term activation (Zivkovic et al. 1974; Lloyd and Kaufman, 1975) . Therefore, the increased activity found in the ventral tegmental area suggests that TH molecules may be induced in A10 dopamine cell bodies following chronic DN-1417 treatment. This is of interest since it is the first evidence for the induction of TH molecules in the A10 dopamine system.
The measurement of immunoprecipitable TH molecules is necessary to demonstrate increased synthesis of the enzyme. In spite of the increased TH activity in the A10 cell bodies, the activity was not elevated in their terminals, the prefrontal cortices, olfactory tuberculum and nucleus accumbens. The basis for the differential responses of TH in cell bodies and nerve terminals is unclear. It is probable that there is a time lag between the initial increase of TH in the cell bodies and the appearance of increased TH in the nerve terminals; if the TH molecules are transported by axonal transport, as described in the noradrenergic neuron system. In addition, the decreased activity found in the terminal regions may be related to either enzyme degradation or release from the terminals (Black, 1975) .
The TH activity in the nigrostriatal dopamine system was not affected by DN -1417, when the activity was assayed at optimal pH and in the presence of saturated cofactor. However, it is possible that DN-1417 enhances the dopamine synthesis in the terminal regions, because the striatal TH is activated in vivo by increasing the affinity of existing molecules for pterin cofactor (see a review by Mandel, 1978) . Since the activity measured at suboptimal pH and in the presence of subsaturated cofactor is sensitive to short term activation, further studies are necessary to detect the effect of DN -1417 on the TH activation in the nerve terminal regions.
In behavioral pharmacological studies, a number of investigations suggest that the behavioral changes induced by TRH treatment, are associated with the central dopaminergic system. Agarwal et al. (1976) observed that repeated administration of TRH caused a marked increase in the spontaneous locomotor activity which was both time-and dose-dependent. Miyamoto and Nagawa (1977) reported that intraperitoneal injection of TRH induced both behavioral excitation and increased locomotor activity.
We also observed a marked increase in spontaneous motor activity for at least 2 hours after intraperitoneal injection of DN -1417 (20 mg/kg/day).
This phenomenon was reproducible for 7 days. The increase in spontaneous motor activity following the injection of DN -1417, confirms a previous report (Miyamoto et al. 1981) . Bilateral injections of TRH (Miyamoto and Nagawa, 1977; Heal and Green, 1979) or TRH analogs, DG-2509 and CG-3703, (Heal et al. 1981) into the nucleus accumbens increase locomotor activity, and the effect of i traaccumbe s injection of TRH was abolished by pretreatment with haloperidol or 6 -hydroxydopamine. Biochemical studies have also shown that TRH (Kerwin and Pycock , 1979) or DN -1417 (Narumi et al. 1982 stimulates dopamine release from slices of rat nucleus accumbens. These findings suggest that the locomotor stimulant action of TRH or its analogs is mediated by the mesolimbic dopamine system.
Our results also provide further evidence for the intimate involvement of mesolimbic and mesocortical dopamine systems in the central actions of DN -1417. On the other hand, chronic DN-1417 increased TH activity in the nucleus arcuatus (A12 dopamine cell bodies) but did not change the TH activity in the median eminence which includes their nerve terminals.
Although DN -1417 has a weak thyrotropin -releasing effect, the analog should exert indirect effects on pituitary function via the A12 dopamine system.
